(-0.04%) 5 476.50 points
(-0.07%) 38 791 points
(-0.01%) 19 920 points
(0.34%) $80.60
(1.22%) $2.82
(0.24%) $2 334.60
(-0.16%) $29.35
(-0.15%) $969.40
(0.01%) $0.932
(-0.16%) $10.64
(0.05%) $0.788
(-1.87%) $86.80
Live Chart Being Loaded With Signals
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer...
Stats | |
---|---|
Šios dienos apimtis | 1.25M |
Vidutinė apimtis | 126 338 |
Rinkos kapitalizacija | 20.90M |
EPS | $-0.240 ( Q1 | 2024-05-15 ) |
Kita pelno data | ( $0 ) 2024-08-08 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-1.037 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (1.42%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-13 | Guerin Mark Patrick | Buy | 8 666 | Common Stock |
2024-03-14 | Guerin Mark Patrick | Sell | 2 591 | Common Stock |
2024-03-13 | Guerin Mark Patrick | Sell | 8 666 | Restricted Stock Units |
2024-03-13 | Fruchtman Steven M | Buy | 23 111 | Common Stock |
2024-03-14 | Fruchtman Steven M | Sell | 8 727 | Common Stock |
INSIDER POWER |
---|
74.56 |
Last 95 transactions |
Buy: 2 889 396 | Sell: 191 603 |
Tūris Koreliacija
Onconova Therapeutics Inc Koreliacija
10 Labiausiai teigiamai susiję koreliacijos |
---|
10 Labiausiai neigiamai susiję koreliacijos |
---|
Ar žinojote?
Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).
Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.
Onconova Therapeutics Inc Koreliacija - Valiuta/Žaliavos
Onconova Therapeutics Inc Finansinės ataskaitos
Annual | 2023 |
Pajamos: | $226 000 |
Bruto pelnas: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2023 |
Pajamos: | $226 000 |
Bruto pelnas: | $226.00B (100 000 000.00 %) |
EPS: | $-0.900 |
FY | 2022 |
Pajamos: | $226 000 |
Bruto pelnas: | $212 000 (93.81 %) |
EPS: | $-0.880 |
FY | 2021 |
Pajamos: | $226 000 |
Bruto pelnas: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Onconova Therapeutics Inc
Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer. It has two clinical-stage programs, including narazaciclib (ON 123300), a multi-targeted kinase inhibitor that is in Phase I study for solid tumors, as well as hematological malignancies as a single agent or in combination with other anti-cancer therapies; and oral rigosertib alone or in combination with PD-1 inhibitor, which is in Phase I/IIa for the treatment of progressive K-Ras mutated non-small cell lung cancer. The company develops a Phase Ib/II ISS with rigosertib monotherapy in patients with advanced squamous cell carcinoma associated with recessive dystrophic epidermolysis bullosa; and has a preclinical program comprising IV/oral rigosertib for COVID-19. It has a license agreement with SymBio Pharmaceuticals Limited; license, development, and commercialization agreement with Pint International SA.; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of narazaciclib. Onconova Therapeutics, Inc. was incorporated in 1998 and is headquartered in Newtown, Pennsylvania.
Apie Signalai gyvai
Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.
Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.